
Apyx Medical Corporation (NASDAQ:APYX – Free Report) – Equities researchers at HC Wainwright boosted their FY2026 EPS estimates for shares of Apyx Medical in a research note issued to investors on Friday, November 6th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.21) per share for the year, up from their prior forecast of ($0.25). The consensus estimate for Apyx Medical’s current full-year earnings is ($0.21) per share. HC Wainwright also issued estimates for Apyx Medical’s Q4 2026 earnings at ($0.04) EPS, Q1 2027 earnings at ($0.06) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.06) EPS, Q4 2027 earnings at ($0.04) EPS and FY2027 earnings at ($0.22) EPS.
A number of other research firms have also recently issued reports on APYX. Maxim Group initiated coverage on shares of Apyx Medical in a research report on Tuesday, September 29th. They set a “buy” rating and a $6.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a research note on Monday, September 21st. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $6.20.
Apyx Medical Trading Up 2.4%
APYX opened at $3.00 on Tuesday. Apyx Medical has a 1-year low of $2.25 and a 1-year high of $5.08. The company has a current ratio of 4.95, a quick ratio of 3.85 and a debt-to-equity ratio of 3.54. The company has a market cap of $126.37 million, a P/E ratio of -15.79 and a beta of 1.47. The company has a fifty day moving average price of $2.73 and a two-hundred day moving average price of $3.57.
Apyx Medical (NASDAQ:APYX – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.05. The business had revenue of $14.03 million for the quarter, compared to analyst estimates of $13.29 million. Apyx Medical had a negative net margin of 14.16% and a negative return on equity of 68.79%.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Nwam LLC bought a new position in Apyx Medical during the first quarter worth about $47,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Apyx Medical in the 2nd quarter valued at $62,000. AXQ Capital LP bought a new position in Apyx Medical in the 2nd quarter valued at $78,000. HighTower Advisors LLC purchased a new position in shares of Apyx Medical during the 3rd quarter valued at $51,000. Finally, Jefferies Financial Group Inc. purchased a new position in shares of Apyx Medical during the 2nd quarter valued at $110,000. 55.33% of the stock is currently owned by hedge funds and other institutional investors.
Apyx Medical Company Profile
Apyx Medical Corporation develops and commercializes energy-based medical technologies for use in surgical and aesthetic procedures. The company’s platform is based on helium plasma technology, which is designed to deliver controlled energy for soft-tissue coagulation, cutting, and contraction. Apyx Medical’s principal product line is Renuvion, a system that combines helium plasma with radiofrequency energy. Renuvion devices and handpieces are used by physicians in a range of surgical and aesthetic applications, including procedures intended to coagulate tissue and address skin laxity.
See Also
- Five stocks we like better than Apyx Medical
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.
